• Tuesday, June 4, 2024 @ 12:00 am

AGAMREE is off to a flying start in the US and EU, with initial sales surpassing expectations. We forecast global peak sales of CHF 750+ mn, which would be transformational. Santhera guides for a cash reach into 2025 (excluding maturing convertible bonds) and expects to reach breakeven on a cash basis by H1 2026.

Key catalysts include:

1. AGAMREE UK launch in DMD (summer 2024)
2. AGAMREE partnerships (during 2024)
3. AGAMREE China approval; launch in France, Italy, Spain, Benelux (Q1 2025)

Santhera Valuation Report

You may also be interested in